Cryofocus Medtech (Shanghai) (HKG:6922) has obtained approval for its Malignant Stenosis Cryoablation System from China's National Medical Products Administration, a Thursday filing with the Hong Kong bourse said.
The product is a self-developed cryoablation system indicated to ablate malignant airway tumor tissue and reduce the frequency of airway restenosis, according to the medical device company.
Price (HKD): $4.83, Change: $-0.15, Percent Change: -3.01%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。